Welcome to our dedicated page for Avantor SEC filings (Ticker: AVTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Avantor, Inc. (NYSE: AVTR) SEC filings, offering a view into the company’s financial reporting, governance updates and material events. Avantor is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries, and its regulatory filings document key aspects of this business.
Through Forms 10-K and 10-Q, readers can review Avantor’s audited annual and quarterly financial statements, along with management’s discussion of results, risk factors and segment information. Current reports on Form 8-K capture material developments such as quarterly earnings announcements, leadership and board changes, amendments to credit facilities, and other significant transactions. For example, recent 8-K filings describe the appointment of a new President and Chief Executive Officer, the creation of an Executive Vice President and Chief Operating Officer role, the election of new independent directors, and amendments to senior secured credit facilities and the termination of an accounts receivable securitization facility.
Avantor’s filings also explain the company’s use of non-GAAP financial measures, including Adjusted Operating Income, Adjusted EBITDA, adjusted net income, adjusted EPS, adjusted net leverage, free cash flow and free cash flow conversion, and provide reconciliations to comparable GAAP measures. Investors can use these disclosures to understand how management evaluates performance and capital structure.
On this page, Stock Titan pairs real-time EDGAR updates with AI-powered summaries that highlight the main points in each filing. Users can quickly identify items related to quarterly results, financing arrangements, governance changes and other topics, while still having access to the full original documents for detailed review.
Avantor director Gregory L. Summe, through a trust, reported an open-market purchase of 100,000 shares of common stock on February 12, 2026 at $9.40 per share. After this transaction, the trust held 400,000 shares indirectly attributed to him.
Separately, Summe also reported 58,111 shares of Avantor common stock held directly. The filing notes that he disclaims beneficial ownership of the trust’s shares except to the extent of his economic interest, meaning the trust is the primary holder of that indirect position.
Avantor reported weaker results for the fourth quarter and full year 2025 and announced a major segment realignment. Fourth-quarter net sales were $1.66 billion, down 1.4% year over year, with organic sales down 4.1%. Net income fell sharply to $52 million, while adjusted EBITDA was $252 million with a 15.2% margin and adjusted EPS of $0.22.
For full year 2025, net sales were $6.55 billion, down 3.4% (2.8% organic decline). The company posted a net loss of $530 million, compared with net income of $712 million in 2024, largely reflecting a $785 million goodwill impairment. Adjusted EBITDA was $1.07 billion with a 16.3% margin and adjusted EPS of $0.90. Operating cash flow remained solid at $624 million, generating free cash flow of $496 million and adjusted net leverage of 3.2x.
Laboratory Solutions full‑year net sales declined 4.6% to $4.40 billion and Bioscience Production declined 1.0% to $2.15 billion, with margins compressing in both. Avantor is executing a “Revival” program, including relaunching the VWR brand and supply chain and e‑commerce improvements, and will realign into two new segments—VWR Distribution & Services and Bioscience & Medtech Products—starting with the first quarter of 2026.
Avantor, Inc. is a global supplier of mission-critical products and services for biopharma and healthcare, education and government, and advanced technologies customers. It operates through Laboratory Solutions and Bioscience Production, combining its VWR distribution channel with proprietary brands like J.T. Baker, NuSil and Masterflex.
The company serves more than 300,000 customer locations in about 180 countries, with over 85% of net sales coming from recurring materials, equipment and services. Around 80% of 2025 transactions ran through its digital channels, supported by integrated ERP and e-commerce platforms.
Avantor is running a multi‑year cost transformation program, now targeting about $400 million in annual gross run‑rate savings by the end of 2027, alongside a refined operating model. Key risks include supply chain constraints and inflation, intense competition, reliance on key suppliers, extensive global regulatory and environmental requirements, cybersecurity and data privacy exposure, climate and sustainability pressures, and a significant debt load with related covenant limits.
Avantor, Inc. reported that director Simon Dingemans received an equity award in the form of restricted stock units. On 01/02/2026, he was granted 6,225 shares of common stock at a price of $0 per share, reflecting a stock-based compensation grant rather than a market purchase. Following this award, he beneficially owned 6,225 common shares in direct form.
According to the disclosure, the grant consists of restricted stock units that are scheduled to vest on May 6, 2026. This means the units convert into common shares for the director only once the vesting date is reached, aligning his compensation with the company’s future performance and continued service.
Avantor, Inc. director reports no share ownership. Simon Dingemans, who serves as a director of Avantor, Inc. (ticker AVTR), filed an initial insider ownership statement indicating that he does not beneficially own any Avantor securities. The filing explicitly notes that no securities are beneficially owned, meaning he reports neither direct holdings nor indirect interests through derivative securities at this time.
Avantor, Inc. disclosed that its Board of Directors has elected Simon Dingemans as a director, effective January 2, 2026. His initial term will run until the company’s 2026 Annual Meeting of Stockholders and he will fill the vacancy created by Jonathan Peacock’s previously announced resignation, which becomes effective December 31, 2025.
Dingemans brings extensive financial and deal-making experience, having served as Chief Financial Officer of GSK plc from 2011 to 2019 and previously holding senior roles at The Carlyle Group, Goldman Sachs and SG Warburg. He currently sits on the boards of Vodafone Group Plc, WPP plc and Genomics Limited. The Board determined that he meets the independence standards of the New York Stock Exchange and the Securities Exchange Act of 1934.
As a non-employee director, he will receive Avantor’s standard compensation: an annual cash retainer of $95,000, paid quarterly, and a grant of restricted stock units with a grant date fair value of $210,000, prorated for his service before the 2026 annual meeting. These restricted stock units are scheduled to vest in full on May 6, 2026, subject to his continued service. Avantor also noted that it issued a press release about his election on December 18, 2025, furnished as an exhibit.
Avantor, Inc. director reported acquiring additional company stock. On December 5, 2025, the insider received 8,106 restricted stock units of Avantor common stock, which vest on May 6, 2026, and are held directly. On the same date, the insider also purchased 350,000 shares of Avantor common stock at a weighted average price of $11.09 per share through a limited liability company, reported as indirectly owned.
The share purchases were executed in multiple trades at prices ranging from $10.98 to $11.21 per share. The reporting person states they will provide full trade-by-trade pricing details upon request and disclaims beneficial ownership of the indirectly held securities except to the extent of any pecuniary interest.
Avantor, Inc. reported that one of its directors filed an initial insider ownership statement effective 12/05/2025. The report indicates that this director does not beneficially own any Avantor securities, including both non-derivative shares and derivative instruments such as options or warrants. The filing is made by a single reporting person on an individual basis and includes a power of attorney authorizing an attorney-in-fact to sign on the reporting person’s behalf.
Avantor, Inc. announced that its Board of Directors has elected Sanjeev Mehra as a director, with an initial term running until the company’s 2026 Annual Meeting of Stockholders. The Board determined he meets the independence standards of the New York Stock Exchange and the Securities Exchange Act of 1934.
Mehra, age 66, is Co‑Founder and Managing Partner of Periphas Capital and previously held senior roles at Goldman Sachs from 1986 to 2017, including Partner and Vice Chairman of the Global Private Equity business. He currently serves on the board of OPENLANE, Inc.
As a non‑employee director, he will receive standard compensation: an annual cash retainer of $95,000, prorated for 2025, and a grant of restricted stock units with a grant date fair value of $210,000, also prorated, vesting in full one year from grant subject to continued service. Avantor also issued a press release about his election, furnished as an exhibit.
Avantor, Inc. (AVTR) disclosed that a reporting person who serves as both President and CEO and a director acquired common stock in the company. On 11/17/2025, this insider purchased 87,500 shares of Avantor common stock at a price of $11.35 per share. Following this open-market purchase, the insider beneficially owns 283,424 shares, held directly.